The potential role of bcl-2, bax, and Ki67 expression in thymus of patients with myasthenia gravis, and their correlation with clinicopathologic parameters

European Journal of Cardio-thoracic Surgery

Volumn 20, Issue 4, 2001, Pages 712-721

  Salakou, S ^a   Tsamandas, A C ^a   Bonikos, D S ^a   Papapetropoulos, T ^a   Dougenis, D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Apoptosis; Bax; Bcl 2; Gene expression; Ki67; Myasthenia gravis; Prognosis; Thymectomy

Indexed keywords

BAX PROTEIN, HUMAN; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYPERPLASIA; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; THYMECTOMY; THYMOMA; THYMUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; FEMALE; HUMANS; HYPERPLASIA; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THYMECTOMY; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 0035491323     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(01)00776-X     Document Type: Article

References (25)

1. Vincent A. Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol Rev 1990;60:756-824.
2. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987;60:2727-2743.
3. Gilhus NE, Jones M, Turley H, Gatter KC, Nagvekar N, NewsomDavis J, Willcox N. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 1995;48:447-455.
4. Jaretzki A, Wolff M. Maximal thymectomy for myasthenia gravis. J Thorac Cardiovasc Surg 1988;96:711-716.
5. Bulkey GB, Bass KN, Stephenson R, Deiner-West M, George S, Reilly PA, Baker RR, Drachman DB. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg 1997;226:324-335.
6. Jaretzki A, Barohn RB, Ernstoff R, Kaminski HR, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendation for clinical research standards. Ann Thorac Surg 2000;70:327-334.
7. Kruger S, Muller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 1995;75:480-484.
8. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845-1853.
9. Cummings MC, Winterford CM, Walker NI. Apoptosis. Am J Surg Pathol 1997;21:88-101.
10. Von Boehmer H. Developmental biology of T cells in T cell-receptor transgenic mice. Annu Rev Immunol 1990;8:531-556.
11. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100-103.
12. Hockenbery D, Nunez G, Milligan C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:33-336.
13. Cleary ML, Sklar J. Nucleotide sequence of a t (14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a break-point cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-7443.
14. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status. Virchows Archiv 1994;424:47-51.
15. Onodera J, Nakamura S, Nagano I, Tobita M, Yoshioka M, Takeda A, Oouchi M, Itoyama Y. Upregulation of Bcl-2 Protein in the myasthenic thymus. Ann Neurol 1996;39:521-528.
16. Oltvai Z, Milliman C, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conversed homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
17. Yang E, Korsmeyer S. Molecular thanatopics: a discourse on the7 BCL2 family and cell death. Blood 1996;88:386-401.
18. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994;145:1323-1336.
19. Penault-Llorca, Bouabdallah R, Devilard E, Charton-Bain MC, Hassoun J, Birg F, Xerri L. Analysis of bax expression in human tissues using the anti-bax 4F11 monoclonal antibody on paraffin sections. Pathol Res Pract 1998;194:457-464.
20. Kirchner T, Muller-Hermelink HK. New approaches in the diagnosis of thymic epithelial tumors. Prog Surg Pathol 1989;10:167-190.
21. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-888.
22. Gratiot-Deans J, Ding L, Turka LA, Nunez G. bcl-2 proto-oncogene expression during human T cell development: evidence for biphasic regulation. J Immunol 1993;151:83-91.
23. Moore NC, Anderson G, Williams GT, Qwen JJ, Jenkinson EJ. Developmental regulation of bcl-2 expression in the thymus. Immunology 1994;81:115-119.
24. Kornstein MJ, Brooks JJ, Anderson AO, Levinson AI, Lisak RP, Zweiman B. The immunohistology of the thymus in myasthenia gravis. Am J Pathol 1984;117:184-194.
25. Fujii N, Itoyama Y, Goto I. Increase in differentiated type of T lineage cells in the myasthenic thymus: two-color fluorocytometric analysis. Ann Neurol 1990;27:642-646.